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BACKGROUND: Although some clinical–pathological features of breast cancers, such as the incidence of ductal cancer in situ (DCIS) and
the diameter of invasive tumours, are sensitive indicators of early detection, comprehensive population-based studies of opportunistic
screening are needed.
METHODS: Cases of DCIS or invasive breast cancer diagnosed in 1996–2007 were identified from the Ticino Cancer Registry (south of
Switzerland). Time trends of age-adjusted incidence and mortality, as well as main clinical–pathological features, such as tumour
diameter, AJCC stage and histological grade, were analysed.
RESULTS: A total of 3047 incident cases of female breast cancer were identified. The proportion of DCIS with respect to invasive cases
increased from 5.8% in the period 1996–2001 to 6.4% in the period 2002–2007. The median tumour size of invasive cancers
decreased from 20mm in 1996–2001 to 18mm in 2002–2007 (Po0.0001). An increase in well/moderately differentiated invasive
tumours, from 67% in the period 1996–2001 to 73% in 2002–2007 (Po0.001), was detected and resulted in an Annual Percentage
Change of incidence of 2.8 (95% confidence interval: 1.3; 4.3).
CONCLUSION: An opportunistic screening strategy can lead to an improvement of prognostic features at diagnosis, but these features
are still less favourable than those achieved by organised screening programmes.
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Owing to the difficulty in implementing primary preventive
measures for breast cancer, secondary prevention is correspond-
ingly important, aimed at maximising detection of small
cancers. Early detection diminishes the likelihood of clinical
symptoms, disease progression, recurrence, distant metastasis, and
death from breast cancer (Tabar et al, 1999). Trials have concluded
that mammography screening in women aged from 50 to 69 can
reduce breast cancer mortality by 25–30% (Gotzsche and Nielsen,
2006). Although Swiss French-speaking regions are covered by
organised screening, the German- and Italian-speaking regions
have no such programme. In the Italian- and French-speaking
parts, physician-prescribed mammography is more frequent than
in the German-speaking parts (Keller et al, 2001). In the south of
Switzerland, the proportion of women aged 50–64 years who
had undergone at least one mammography examination
increased from 85% in 2002 to 88% in 2007 (Federal Office of
Statistics, 2008).
The current coexistence of systematic screening programmes
and opportunistic screening strategies in Switzerland with its high-
quality health-care system provides an opportunity to investigate
the merits and drawbacks of the two approaches (Zwahlen et al,
2004). Although both methods seem effective in reducing breast
cancer mortality, data on opportunistic screening are limited
(de Gelder et al, 2009).
The aim of this ecological population-based study was to assess
such indicators as incidence rates, percentage of small cancers,
stage distribution at diagnosis, axillary lymph node status and
corresponding time trends for newly detected breast cancers, and
to compare our data with those from populations with
programmed screening.
MATERIALS AND METHODS
Patients with a primary diagnosis of ductal cancer in situ (DCIS) or
invasive breast cancer diagnosed between 1996 and 2007 were
selected from the Ticino Cancer Registry located in the south of
Switzerland, where more than 80% of women aged 50–69 years
regularly undergo mammography (Bordoni and Mazzola, 2007;
Bordoni et al, 2009).
Topography and morphology classifications followed the Inter-
national Classification of Diseases for Oncology (ICD-O-III) and
the WHO Classification of Breast Tumours (Fritz et al, 2000;
Tavassoli and Devilee, 2003). Case registration followed the
International Agency for Research on Cancer (IARC) guidelines
and European Network of Cancer Registries (ENCR) recommen-
dations (Tyczynski et al, 2003).
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lymphoma, sarcoma and phyllodes tumours were excluded from
the analysis.
Essential information was abstracted from pathology reports,
including tumour diameter, lymph node status, stage group (AJCC,
5th and 6th editions), histological grade (Bloom-Richardson
system and the Elston and Ellis modification), laterality and
hormonal receptor status. DCIS were graded according to nuclear
features (European Commission, 1996; Shoker and Sloane, 1999).
Individuals who received preoperative/neoadjuvant treatment (less
than 5%) were excluded from analyses of tumour stage and
diameter. Breast cancers expressing ER and PR in less than 5% of
neoplastic cells were considered as negative for hormone receptor
expression (Spitale et al, 2009). All histopathological analyses were
carried out by a single laboratory and evaluated on routinely
collected tissues by the same group of pathologists to ensure
reproducibility.
Statistical analysis
Mean and median values were provided for quantitative variables,
whereas proportions represented qualitative variables. Differences
between two periods (1996–2001 vs 2002–2007) were evaluated
using Student’s T-test for continuous variables and w
2 or Fisher’s
exact test for discrete variables (Armitage et al, 2002). Age-
standardised incidence and mortality rates were calculated by the
direct method (Esteve et al, 1994). Incidence rates of invasive and
in situ lesions were produced for different age groups, for the
above two periods and for single calendar years. Trends in
incidence and mortality were measured as the estimated annual
percentage change (APC) and the 95% confidence intervals (CIs)
(Kleinbaum et al, 1988). Joinpoints representing the years when
the trend changed were identified (Kim et al, 2000; National
Cancer Institute, April 2005). Time trends were also analysed for
mean and median tumour diameter, AJCC stage distribution
(considering the shift from advanced to early stages), as well as
histological grade at diagnosis. Statistical significance was
determined at Po0.05 and the SAS System Version 9.1 (SAS
Institute Inc., Cary, NC, USA) was used for analysis.
RESULTS
A total of 3047 incident cases of female breast cancer were
identified in the study period, of which 187 (6. 1%) were DCIS and
2860 (93.9%) invasive carcinomas.
Patient and invasive tumour characteristics are summarised for
the two periods in Table 1. The mean patient age was 63.0 years,
with no significant change during the study. About 80% of cases
were diagnosed after age 50 years, those with in situ cancer being
significantly younger (60.9 years) than those with invasive cancer
(P¼0.0198, data not shown); the proportion of in situ cases was
higher among patients aged 50–69 years (57.7%), with a lower
proportion aged 70 years or over (24.1%).
Among invasive cancers, we found that the mean diameter (data
available for 85% of cases) decreased by 9%, from 22.0±13.2 to
20.3±12.6mm, between 1996–2001 and 2002–2007 (P¼0.0008);
the corresponding medians decreased by 11% from 20 to 18mm
(Po0.0001). A decreasing trend of mean (APC: 1.3; 95% CI:  2.1;
 0.5) and median (APC: 1.5; 95% CI:  2.5;  0.4) tumour size
was detected from 1996 to 2007. A similar but stronger pattern was
observed in the age group 50–69 years, with a significant
reduction in mean (APC:  2.1; 95% CI:  3.1;  1.1) and median
size (APC:  2.5; 95% CI:  3.9;  1.1). We also noted an increase in
the number of tumours with a diameter p10mm or 11–20mm in
the more recent period, whereas cases with a diameter greater than
20mm declined, both at all ages (P¼0.0441, Table 1) and in the
age group 50–69 years (P¼0.1821, data not shown).
Overall, 40% of invasive cancers were associated with lymph
node metastases at diagnosis, the respective proportions being
43.4% in women younger than 50 years, 42.3% in the age group
50–69 years and 34.2% at age of 70 years or over (data not shown).
Comparing the two periods, there was no significant change in the
proportion with lymph node metastases compared with those with
no nodal involvement, even after age stratification. The mean and
median numbers of examined lymph nodes decreased significantly
from 2001 onwards, with an APC equal to  10.5 (95% CI:  13.8;
 7.0) and  18.7 (95% CI:  25.1;  11.8), respectively, the pattern
being similar at the age of 50–69 years. Simultaneously, the use of
sentinel node procedure increased from zero in 1996 to 60.4% in
2007 (data not shown). Only 6% of invasive cancers presented
distant metastases at diagnosis with no significant trend over the
study period.
More than 80% of invasive cases were diagnosed at stage I or II.
The proportion of women with stage I increased from 38.1% in
1996–2001 to 42.2% in 2002–2007 (Table 1) with similar results
for ages 50–69 years, with a higher percentage of stage I cases in
the last period (40.4% in 1996–2001 vs 45.7% in 2002–2007,
P¼0.3197). The results were confirmed when age-standardised
incidence trends were observed (Figure 1).
Well/moderately differentiated invasive lesions increased (from
67% in 1996–2001 to 73% in 2002–2007), whereas poorly
differentiated cancers declined (P¼0.0003); results for the age
group 50–69 years were similar. An opposite but not significant
trend was observed in the two periods for in situ lesions; a
decrease of well/moderately differentiated cancers (from 58.3 to
44.3%) was accompanied by an increase in poorly differentiated
cancers (from 41.7 to 55.7%). Considering the age-standardised
incidence rates, we found a significant increase (APC: 2.8; 95% CI:
1.3; 4.3) in well/moderately differentiated invasive cancers and a
decrease (APC:  1.3; 95% CI:  4.7; 2.3) in poorly differentiated
invasive cancers (Figure 2). In DCIS cases, both well/moderately
(APC: 13.3; 95% CI: 0.5; 27.9) and poorly (APC: 33.8; 95% CI: 4.0;
72.3) differentiated lesions increased.
Of the 2860 new cases of invasive breast cancer diagnosed in the
period 1996–2007, 1273 (44.5%) occurred in women in the target
age group (50–69 years) for mammography screening. The overall
World age-standardised incidence rate was equal to 79.6 cases per
100000 women with an APC of 0.9 (95% CI:  0.8; 2.7). The
incidence trend in pre-menopausal women was substantially stable
(APC:  0.7; 95% CI:  4.7; 3.5), whereas at ages 50–69 and 70þ
years, an increasing trend was observed, though the estimated
APCs were not statistically significant.
Of the 187 DCIS, 34 (18%) occurred before the age of 50 years,
108 (58%) at ages 50–69 years and the remaining 45 (24%) at ages
70þ years. The proportion of DCIS among the 3047 incident cases
included in the study (DCIS and invasive tumours) increased from
5.8% in the period 1996–2001 to 6.4% in the period 2002–2007,
and markedly in the final 2 years, when it reached 10%; at ages 50–
69 years, this increased from 7.2% in 1996–2001 to 8.4% in 2002–
2007 (data not shown).
Over the 12-year study period, the overall incidence of DCIS in
Ticino was 5.7 cases per 100000 women, and this remained
essentially constant until 2005 (Figure 1). The final 2-year data
(2006–2007), however, suggests an increase in world age-adjusted
incidence (11.5 cases per 100000), a pattern also observed
after stratification by age group. The age-standardised incidence
for DCIS among women in the target age group (50–69 years)
increased between 1996–2001 and 2002–2007 (19.2 and 24.4
cases per 100000, respectively); the rate for those aged 70 years or
over also showed an upward trend (from 14.0 to 20.4 cases per
100000).
The overall age-adjusted mortality rates of breast cancer in
Ticino decreased from 20–22 cases in the 1980s to 14.6 cases per
100000 in 2005, with a significant APC equal to  1.4 (95% CI:
 2.4;  0.5). Mortality below age 50 years started to decrease
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Variable All invasive cases, n¼2860 1996–2001, n¼1328 (46.4%) 2002–2007, n¼1532 (53.6%) P-value
Age
Mean±s.d. (years) 63.0±14.5 62.7±14.8 63.3±14.3 0.2915
Median 63 62 63 0.1759
Age-specific groups, n (%)
o50 591 (20.7) 284 (21.4) 307 (20.0) 0.6420
50–69 1273 (44.5) 582 (43.8) 691 (45.1)
469 996 (34.8) 462 (34.8) 534 (34.9)
Pre-menopausal (agep51), n (%) 695 (24.3) 343 (25.8) 352 (22.9) 0.0762
Post-menopausal (age451), n (%) 2164 (75.7) 985 (74.2) 1180 (77.0)
Basis of diagnosis
Non-microscopic 26 (0.9) 9 (0.7) 17 (1.1) 0.0021
Cytology 110 (3.8) 69 (5.2) 41 (2.7)
Histology 2707 (94.7) 1240 (93.4) 1467 (95.8)
DCO 17 (0.6) 10 (0.7) 7 (0.4)
Tumour size
Mean±s.d. (mm) 21.1±12.9 22.0±13.2 20.3±12.6 0.0008
Median 19 20 18 o0.0001
Size-specific groups, n (%)
p1.0cm 383 (15.8) 165 (14.6) 218 (16.9) 0.0441
1.0–2.0cm 1082 (44.7) 486 (43.1) 596 (46.0)
2.0–5.0cm 888 (36.7) 446 (39.6) 442 (34.1)
45.0cm 69 (2.8) 30 (2.7) 30 (3.0)
Unknown or set after therapy 438 201 237
Lymph node status, n (%)
Positive 1032 (40.0) 491 (40.5) 541 (39.5) 0.5862
Negative 1551 (60.0) 721 (59.5) 830 (60.5)
Missing or set after therapy 277
Clinical behaviour, n (%)
M0 2591 (94.0) 1197 (93.6) 1394 (94.3) 0.4230
M1 166 (6.0) 82 (6.4) 84 (5.7)
Unknown 103 49 54
AJCC stage group, n (%)
Stage I 1023 (40.2) 464 (38.1) 559 (42.2) 0.2045
Stage II 1041 (40.9) 520 (42.7) 521 (39.3)
Stage III 314 (12.4) 152 (12.5) 162 (12.2)
Stage IV 166 (6.5) 82 (6.7) 84 (6.3)
Unknown or set after therapy 316 110 206
Histological type, n (%)
Ductal 2308 (80.7) 1090 (82.1) 1218 (79.5) 0.0048
Lobular 309 (10.8) 121 (9.1) 188 (12.3)
Mixed ductal and lobular 69 (2.4) 25 (1.9) 44 (2.9)
Other 174 (6.1) 92 (6.9) 82 (5.3)
Histological grade (Elston/Ellis), n (%)
Well/moderately differentiated 1876 (70.4) 821 (67.0) 1055 (73.3) 0.0003
Poorly differentiated 789 (29.6) 405 (33.0) 384 (26.7)
Unknown/unclassified 195 103 92
Laterality, n (%)
Right 1357 (48.3) 632 (48.2) 725 (48.3) 0.9624
Left 1453 (51.7) 678 (51.8) 775 (51.7)
Unknown 50 18 32
ER status, n (%)
Positive 2095 (81.8) 874 (77.1) 1221 (85.4) o0.0001
Negative 467 (18.2) 259 (22.9) 208 (14.6)
Unknown 298 195 103
PR status, n (%)
Positive 1759 (68.8) 713 (63.2) 1046 (73.1) o0.0001
Negative 799 (31.2) 415 (36.8) 384 (26.9)
Unknown 302 200 102
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 33.0;  2.6); a significant decrease was detected from 1990 in the
age group 50–69 years (APC:  3.5; 95% CI:  6.0;  0.9); however,
for women aged over 69 years, there was no change in breast
cancer mortality over time.
DISCUSSION
The role of cancer registries in evaluating breast cancer screening
has been highlighted in recent guidelines (Perry et al, 2008), and
they can also provide population-based breast cancer data
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Figure 1 Trend of breast cancer incidence according to stage. Ticino (south of Switzerland), 1996–2007.
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screening programme or by opportunistic mammography or
clinical means, thereby permitting an evaluation of a screening
strategy for the whole population. Normally, essential quality
parameters can be produced for an organised screening pro-
gramme (Swedish Organised Service Screening Evaluation Group,
2007; NHS Breast Screening Programme, 2008; Perry et al, 2008),
and cancer registries can also provide early indicators of screening
efficacy, without waiting for the mortality data (Schaffer et al,
1996). We focused on specific indicators, and compared our results
for an opportunistic screening with data obtained from other
European and US population-based studies (Table 2). It is
important here to stress that the different degrees of completeness,
as well as age and ethnical distribution within these studies, have
to be taken into account when interpreting differences between our
and other findings.
Although not statistically significant, women overall, and particu-
larly those aged 50–69 years, showed a downward stage shift, with an
increase in stage I and a slight decrease in stage II cases compatible
with what we expected from the literature (Coburn et al,2 0 0 4 ;
Louwman et al, 2008). With respect to the change of TNM
classification in 2003, no significant APC in the age-adjusted
incidence trend according to stage was observed, as in other studies
(Louwman et al, 2008), making it unlikely that the TNM change had
influenced our results. The percentage of stage I cases (40.2% overall)
was comparable to that in European regions with organised
screening programmes (the Netherlands 39%, Denmark 43%), but
was lower than that in Rhode Island, United States (53.5%) (Coburn
et al,2 0 0 4 ;J e n s e net al, 2008; Louwman et al, 2008).
The downward stage shift observed in southern Switzerland was
accompanied by a decreasing trend of invasive tumour size at the
time of diagnosis. The significant decrease in both median
(Po0.0001) and mean (P¼0.0008) diameter showed that early
detection was also effective at this level. Taken together, the data
suggest that an opportunistic screening here has been associated
not only with an increased awareness of breast cancer in the
population and among general practitioners, but also with the
availability of high-quality diagnostic imaging. Nevertheless, the
median and mean sizes are higher than those reported for Rhode
Island, which has organised screening with 80% biannual
attendance, (Table 2) (Coburn et al, 2004). Similarly, in Denmark,
a median tumour with a diameter equal to 20mm was observed in
two regions where no organised screening was implemented, and
that equal to 15mm in a region where one was (Jensen et al, 2008).
When we performed a subgroup analysis that considered tumour
size for the period 2000–2005 (with the aim of making comparison
with other studies without a period bias), the proportion of
tumours with a diameter p10mm was 18.2% in Ticino, whereas in
the Cantons of Geneva and Vaud, with population-based screen-
ing, this reached 26.1 and 30.1%, respectively (Table 2) (Schopper
and de Wolf, 2007; Bulliard et al, 2009). In view of the difficulty in
the pathological determination of the DCIS diameter, this was not
analysed (Thomson et al, 2001; European Commission, 2006).
The trend, described above, of reduced tumour diameter at
diagnosis should be biologically followed by a decrease in the
detection of positive lymph nodes. However, we detected an
essentially constant trend of positive lymph node incidence
between 1996 and 2007. This finding could be attributed to
competitive effects, such as the introduction of the sentinel lymph
node procedure that has been adopted during recent years, as
well as the improved histological workup associated with the
multiple level investigation of lymph nodes, which has also
been introduced by pathologists (Cserni, 1999; Kiaer et al, 2008;
Madsen et al, 2008).
Table 2 Comparison of major indicators among screening programme guidelines, Ticino (south of Switzerland) data and other population-based studies
Parameter
Screening
Programme
Guidelines
Ticino
(south of
Switzerland)
1996–2007 Other population-based studies
a
Proportion of in situ cancers NA 6.1% 7.4 and 10% in the Netherlands
b,c
13 and 15% in the United States
d,e
Proportion of in situ cancers (50–69 years) 10–20% 8.4% 11.6% in the Netherlands
c
12.3% in Geneva
f,g
12.5% in Vaud
f,g
Proportion of invasive cancers with tumour size
p10mm (50–69 years)
X25–30% 18.2%
h 26.1% in Geneva
f,g
30.1% in Vaud
f,g
Proportion of invasive cancers with tumour size
p20mm (50–69 years)
NA 63.5%
h 70.4% in Geneva
f,g
70.1% in Vaud
f,g
Median tumour size for invasive cancers (mm) NA 19mm 15mm in Rhode Island
d
15mm in Denmark
i
20mm in Denmark
i
Mean tumour size for invasive cancers (mm) NA 21mm 20mm in Rhode Island
d
Proportion of invasive cancers with negative
lymph node
470–75% 60% 53.7% in Denmark
i
43.3% in Denmark
i
64.7% in Rhode Island
d
Proportion of invasive tumours with stage I NA 40.2% 39% in the Netherlands
b
43% in Denmark
i
29% in Denmark
i
53.5% in Rhode Island
d
Proportion of invasive tumours with stage II+ o25–30% 59.8% 57% in the Netherlands
b
46.5% in Rhode Island
d
Abbreviation: NA¼not available.
aAll results come from regions where an organised screening programme is implemented, with the exception of those reported in italics,
resulting from opportunistic screening.
bLouwman et al (2008).
cvan Steenbergen et al (2008).
dCoburn et al (2004).
eMalmgren et al (2008).
fBulliard et al (2009).
gSchopper and
de Wolf (2007).
hData for the period 2000–2005, with the aim of being comparable with other Swiss data (i.e., Geneva and Vaud).
iJensen et al (2008).
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(high grade) are probably associated with a significantly higher
risk for invasive carcinoma (Vainio, 2002). High-grade DCIS shows
abnormal mammography features more frequently than does low-
grade DCIS, because of more obvious calcification. We observed
an increase in poorly differentiated DCIS (Figure 2) that may
reflect increased use of mammography and also could represent a
downstaging from invasive to in situ cancers, as hypothesised
(Sumner et al, 2007). We found an increasing trend of well/
moderately differentiated invasive cases, accompanied by a
decrease in high-grade cancers, that could be associated with
early detection (Tabar et al, 1999; Schopper and de Wolf, 2007).
Ductal cancer in situ should increase when a screening
programme is implemented (Miller et al, 2000; van Steenbergen
et al, 2008) and increases have been reported from population-
based studies in the United States, Australia, Italy and the
Swiss Canton of Vaud (Levi et al, 1997; Barchielli et al, 1999;
Kricker et al, 2004; Li et al, 2005). In southern Switzerland, we
observed, among all tumours analysed (DCIS and invasive cases), a
proportion of DCIS equal to 6.4% in the period 2002–2007, similar
to that reported in two studies in the Netherlands (10% in 2000–
2004 and 7.4% in 1984–2006), but our estimates are lower than
in some US studies (13 and 15% in 1987–2001 and
1999–2005, respectively) (Table 2). Although a real difference in
the incidence of breast lesions in Europe compared with North
America cannot be excluded, it is important to highlight that the
pathology criteria could be different. For the target age group
50–69 years, our observed 8.4% of in situ cancers is close, though
not equal to what was reported from the Netherlands (11.6%),
Geneva (12.3%) and Vaud (12.5%), where population screening
programmes are implemented (Table 2). In the final 2 years of
observation, the proportion of DCIS increased to 10%, along with
the introduction of digital mammography and vacuum-assisted
needle core biopsy (Thomson et al, 2001; Pisano et al, 2005).
Considering the mortality, both earlier diagnosis because of
screening and better treatment may have had a role in the
declining rate observed in the United States and some European
countries (Schopper and de Wolf, 2009). A decreasing trend
was reported in Switzerland generally, as well as in southern
Switzerland for all ages and particularly in the age group 50–69
years, irrespective of the screening programme. Most likely,
mortality as a quality indicator does not have enough resolution
to discriminate between systematic and opportunistic screening.
Although the introduction of mass screening is the most likely
explanation for the increased incidence of particularly early stage
invasive breast cancer, increasing exposure to risk factors is also
relevant (Louwman et al, 2008). Factors such as younger age at
menarche, older age at menopause, older age at the birth of first
child, lower parity, and shorter lactation have changed adversely
over the past decade and so have probably contributed to the
observed increase (MacMahon, 2006). Recently, the beginning of a
decline in invasive cancers has been reported, attributed both to an
increase in mammography-detected in situ cases and, particularly
in the United States, a contemporaneous decline in the use of
hormone replacement therapy (Jemal et al, 2007; Ravdin et al,
2007; Malmgren et al, 2008). However, the increasing trend of
invasive breast cancers in the south of Switzerland, together with
the stage shifting described above, along with tumour diameter
decrease and in situ cancer increase, seems to be because of a
progressive increase in the use of early detection diagnostics.
The increasing trend of positive prognostic factors shows that
opportunistic mammography screening can make a substantial
contribution to breast cancer diagnosis; yet the data also show that
there is room for additional improvement in early detection in
comparison with features achieved where organised screening is
established.
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